The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

Through the issuance of Inauguration Day executive orders, the Trump Administration signaled its apparent intent to tackle ...

Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short ...

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

President Trump will continue to pursue the policy of Medicare ... said the CMS in its statement. Trump is planning to issue an executive order supporting drug price negotiations under the IRA ...

AAM said that by including drugs with generics and biosimilars in development in the 15 drugs selected for negotiation, CMS ...

The National Community Pharmacists Association has told CMS that more than 90% of independent pharmacies may choose to stop stocking drugs included in the Medicare Drug Price Negotiation Program due ...

Robert F. Kennedy Jr. said he would follow the Trump administration’s orders on prescription drug price negotiations, a ...

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for older adults and people with disabilities.

Medicare beneficiaries may pay less for 15 additional prescription drugs as early as 2027 as part of the next round of federal regulators' price negotiations with pharmaceutical manufacturers.

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.